During 2013–2016, novel agents, led by Bruton's tyrosine kinase (BTK) inhibitors along with other oral agents such as lenalidomide, bortezomib, temsirolimus, and venetoclax, which are generally well-tolerated and effective, represented the second wave of a clinical revolution that has significantly improved treatment options and outcome among patients with MCL (14, 15). This evidence concerns the gene BTK and mantle cell lymphoma.